Zappy Health review

Two prices are genuinely billed monthly

Zappy Health’s compounded plans list $249 per month for semaglutide and $349 per month for tirzepatide, with all doses included. Those are the monthly purchase options to compare with another recurring plan. The number of medication weeks supplied per monthly payment is not clearly defined, so do not turn the billing unit into a claim about a particular thirty-day or four-week supply.

Three-month packages cost $687 for semaglutide or $987 for tirzepatide; six-month packages cost $1,254 or $1,794. Those totals are prepaid commitments. Their lower monthly equivalents do not establish smaller monthly installments or the same flexibility as the $249 and $349 options. Confirm the actual dispensing schedule and conditions before paying for several months.

The lowest starter offers have additional restrictions

Zappy also advertises three-month introductions at $477 for semaglutide and $837 for tirzepatide, restricted to new users in selected states. Those are not the ordinary recurring prices and are not available to every patient. Ask whether the introduction applies, what it supplies and which payment follows the introductory term.

The longer packages have described all vials shipping together. That makes the pharmacy’s actual packaging, storage and use instructions important. A purchased treatment period does not establish that one opened container can be used throughout it. Obtain the instructions for the dispensed product and the policy if the clinician changes treatment after the pharmacy has fulfilled the order.

The FDA letter belongs to this operator and domain

The FDA issued warning letter 717991, to Kare Solutions, LLC doing business as Zappy. The letter identifies Zappy Health's website and the Fay Avenue address also appearing in the company’s terms. That is a specific operator and website connection, rather than an allegation inferred from a similar business name.

The letter concerned false and misleading claims and misbranding. Subsequent public copy removed the cited phrases in the earlier follow-up, but a wording change does not itself establish an FDA close-out or resolve every question about compliance. Keep the dated regulatory finding separate from the current medication price and from any individual assessment of treatment suitability.

The brand route charges for care separately

Zappy also describes Wegovy and Zepbound prescribing through a $99 monthly care arrangement, with medication billed separately through the relevant pharmacy or manufacturer route. That is not a $99 complete brand-drug offer. Obtain the current product- and dose-specific medication amount and add the applicable care charge when comparing alternatives.

The distinction between brand and compounded treatment should remain explicit throughout the assessment. A familiar active ingredient does not make a compounded formulation the approved brand product. Ask the clinician to identify the actual prescription and pharmacy, explain the treatment choice and clarify how follow-up and prescription changes are handled within the selected payment arrangement.

Compare the total commitment with the care provided

Zappy’s published footprint excludes Hawaii. Its legal documents also carry different corporate addresses, so identify the agreement and contact responsible for the actual order. Before selecting a package, confirm state access, cancellation deadlines, refund conditions and how clinical questions reach the treating professional after medication arrives.

The public material does not establish a dedicated postpartum, breastfeeding or PCOS pathway. Zappy may be relevant to someone comparing a clearly priced monthly option with prepaid programs or a separate brand-care route. The decision must also weigh the specific FDA warning and the actual clinical relationship. Keep the standing monthly amount, conditional starter offer and prepaid total distinct rather than allowing the smallest equivalent to answer every question.